Name | Bilastine |
Description | Bilastine (Bilaxten) is a novel new-generation antihistamine that is highly selective for the H1 histamine receptor, has a rapid onset and prolonged duration of action. |
In vitro | Bilastine has a highly selective affinity for the H1-receptor but a very low affinity for 30 other tested receptors. It isn't obvious inhibitory against bradykinin, serotonin, muscarinic M3-receptors, leukotriene D4, calcium, α1-adrenoceptors, β2-adrenoceptors, and H2- and H3- receptors. |
In vivo | In patients with allergic rhinoconjunctivitis, Bilastine is efficacious in all nasal symptoms including obstruction and in eye symptoms. In the fasting state, Bilastine is quickly absorbed, but the absorption is slowed when it is taken with food or fruit juice. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : Slightly soluble
|
Keywords | Inhibitor | inhibit | Bilastine | Histamine Receptor |
Inhibitors Related | Meclizine dihydrochloride | Mirtazapine | Lidocaine | Famotidine | Mebhydrolin napadisylate | Sodium butanoate | Amitriptyline hydrochloride | Alginic acid | Trazodone hydrochloride | Mianserin hydrochloride |
Related Compound Libraries | Bioactive Compound Library | Pain-Related Compound Library | Membrane Protein-targeted Compound Library | EMA Approved Drug Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Anti-Cancer Approved Drug Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Drug Library |